Yi Shen
Nanjing University
6 Papers
Yi Shen is an academic researcher from Nanjing University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Discovery and validation of extracellular vesicle-associated miRNAs as noninvasive detection biomarkers for early-stage non-small-cell lung cancer.
Yujie Zhong,Xiaoyu Ding,Yuying Bian,Jing Wang,Wanqing Zhou,Xiangdong Wang,Pumin Li,Yi Shen,Junjun Wang,Jing Li,Chunni Zhang,Cheng Wang +11 more
TL;DR: In this paper, the authors used TLDA to identify miRNAs in circulating extracellular vesicles (EVs) for early stage non-small-cell lung cancer (NSCLC) diagnosis.
29
Exploration of the optimal number of regional lymph nodes removed for resected N0 NSCLC patients: A population-based study
TL;DR: This study suggests that ≥ 4 L NRs can yield better survival outcomes compared with 1-3 LNRs in N0 NSCLC patients, and suggests that whites, males, not upper lobe, large cell carcinoma and others, advance T stage or AJCC stage, no surgery, no LNR, no radiation, no chemotherapy, elder age at diagnosis, singled marital status and low family income had negative impact on prognosis.
Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report
TL;DR: This is the first report displaying the clinical efficacy of dacomitinib for patients with delE709_T710insD, which may help to provide alternatives in non-classical variant NSCLC patients.
1
[Safety Analysis of Perioperative Period in Non-Small Cell Lung Cancer Patients with Comorbid Pneumoconiosis].
Yang Yuan,Yu Fei Zhou,Wei Chen,Yi Shen,Yunfeng Zhou +4 more
- 01 May 2022
TL;DR: NSCLC patients with comorbid pneumoconiosis face relatively greater risks during the perioperative period when they undergo radical resection for lung cancer, and the close attention of surgeons and the nursing staff should be raised accordingly.
A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.
Cheng Wang,Meng Ding,Ming-De Xia,Sidi Chen,Anh Van Le,Rafael W. Soto-Gil,Yi Shen,Nan Wang,Junjun Wang,Wan-Jian Gu,Xiangdong Wang,Yanni Zhang,Ke Zen,Xi Chen,Chunni Zhang,Chen-Yu Zhang +15 more
TL;DR: This five-serum miRNA panel was capable of distinguishing NSCLC from benign nodules with an AUC of 0.979 and allowed correct prediction of 86% and 95% stage I–II tumors in the Chinese and American cohorts, respectively.